Department of Cornea & Refractive services, Aravind Eye, Hospital and postgraduate institute of Ophthalmology, Tirunelveli, Tamil Nadu, India.
Department of Cornea & Refractive services, Aravind Eye Hospital, Pondicherry, India.
Semin Ophthalmol. 2024 Jul;39(5):340-352. doi: 10.1080/08820538.2024.2309533. Epub 2024 Feb 1.
Viral keratitis is a significant cause of ocular morbidity and visual impairment worldwide. In recent years, there has been a growing understanding of the pathogenesis, clinical manifestations, and diagnostic modalities for viral keratitis. The most common viral pathogens associated with this condition are adenovirus, herpes simplex (HSV), and varicella-zoster virus (VZV). However, emerging viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Vaccinia virus can also cause keratitis. Non-surgical interventions are the mainstay of treatment for viral keratitis. Antiviral agents such as Acyclovir, Ganciclovir, and trifluridine have effectively reduced viral replication and improved clinical outcomes. Additionally, adjunctive measures such as lubrication, corticosteroids, and immunomodulatory agents have alleviated symptoms by reducing inflammation and facilitating tissue repair. Despite these conservative approaches, some cases of viral keratitis may progress to severe forms, leading to corneal scarring, thinning, or perforation. In such instances, surgical intervention becomes necessary to restore corneal integrity and visual function. This review article aims to provide an overview of the current perspectives and surgical interventions in managing viral keratitis. The choice of surgical technique depends on the extent and severity of corneal involvement. As highlighted in this article, on-going research and advancements in surgical interventions hold promise for further improving outcomes in patients with viral keratitis.
病毒性角膜炎是全球范围内导致眼部发病率和视力损害的重要原因。近年来,人们对病毒性角膜炎的发病机制、临床表现和诊断方法有了更深入的了解。与这种疾病相关的最常见的病毒病原体是腺病毒、单纯疱疹病毒(HSV)和水痘带状疱疹病毒(VZV)。然而,巨细胞病毒(CMV)、EB 病毒(EBV)和牛痘病毒等新兴病毒也可能引起角膜炎。非手术干预是病毒性角膜炎治疗的主要方法。阿昔洛韦、更昔洛韦和三氟胸苷等抗病毒药物有效地减少了病毒复制,改善了临床结果。此外,通过减轻炎症和促进组织修复,辅助措施如润滑、皮质类固醇和免疫调节剂也缓解了症状。尽管采取了这些保守方法,一些病毒性角膜炎病例仍可能进展为严重形式,导致角膜瘢痕、变薄或穿孔。在这种情况下,手术干预成为恢复角膜完整性和视力功能的必要手段。本文旨在综述目前在管理病毒性角膜炎方面的观点和手术干预措施。手术技术的选择取决于角膜受累的程度和严重程度。正如本文所强调的,手术干预方面的持续研究和进展为病毒性角膜炎患者的治疗结果提供了进一步改善的希望。